<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="26537">Retinoid</z:chebi> X receptor (RXR) has been implicated in several <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">neoplastic diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Previously, we have shown that RXR-α is downregulated in human and rodent <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colonic tumors</z:e>, suggesting a potential target for <z:hpo ids='HP_0003003'>colon cancer</z:hpo> prevention (http://www.<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>.org/<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e>/ColonandRectumCancer/DetailedGuide/<z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal-cancer</z:e>-key-statistics) </plain></SENT>
<SENT sid="2" pm="."><plain>Experiments were designed to assess the chemopreventive efficacy of the selective RXR <z:chebi fb="4" ids="48705">agonist</z:chebi> <z:chebi fb="0" ids="50859">bexarotene</z:chebi> for the suppression of intestinal <z:mp ids='MP_0002006'>tumorigenesis</z:mp> in Apc(Min/+) mice </plain></SENT>
<SENT sid="3" pm="."><plain>Before the efficacy studies, we determined that the maximal tolerated dose in C57BL/6J mice was less than 400 ppm </plain></SENT>
<SENT sid="4" pm="."><plain>For the efficacy study, 6-week-old male and female C57BL/6J-Apc(Min/+) mice (nine mice per group) were fed diets containing 0, 30, and 60 ppm of <z:chebi fb="0" ids="50859">bexarotene</z:chebi> or 200 ppm of <z:chebi fb="0" ids="50859">bexarotene</z:chebi> for 80 days before <z:e sem="disease" ids="C0021841" disease_type="Neoplastic Process" abbrv="">intestinal tumors</z:e> were evaluated </plain></SENT>
<SENT sid="5" pm="."><plain>Dietary administration of 30 and 60 ppm of <z:chebi fb="0" ids="50859">bexarotene</z:chebi> suppressed the intestinal <z:mpath ids='MPATH_491'>polyp</z:mpath> formation by 38% (P &lt; .015) and 60% (P &lt; .0001) in males, respectively, and by 8.5% and 37% (P &lt; .007) in females, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Also, significant inhibition (50%-100%) of <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colonic tumor</z:e> formation was observed in both male and female mice with <z:chebi fb="0" ids="50859">bexarotene</z:chebi> treatment </plain></SENT>
<SENT sid="7" pm="."><plain>Administration of 200 ppm of <z:chebi fb="0" ids="50859">bexarotene</z:chebi> showed significant suppression of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> formation (66%, P &lt; .0001); however, it had significant toxicity </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C0021841" disease_type="Neoplastic Process" abbrv="">Intestinal tumors</z:e> of <z:chebi fb="0" ids="50859">bexarotene</z:chebi>-fed mice showed significantly reduced expression of proliferating cell nuclear antigen (60%, P &lt; .0001), cyclin D1, and cyclooxygenase 2 and increased RXR-α <z:chebi fb="5" ids="33699">messenger RNA</z:chebi> and uptake of <z:chebi fb="0" ids="30823">oleate</z:chebi> (34%, P &lt; .01) </plain></SENT>
<SENT sid="9" pm="."><plain>Also, <z:chebi fb="0" ids="50859">bexarotene</z:chebi>-fed mice showed dose-dependent suppression of serum <z:chebi fb="4" ids="17855">triglycerides</z:chebi> (25%-72%, P &lt; .0001) and inflammatory cytokines </plain></SENT>
</text></document>